RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 Evolving MS Treatment Strategies
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 29
SP 26
OP 29
DO 10.1177/155989771429020
UL http://mdc.sagepub.com/content/14/29/26.abstract
AB The assessment of disease activity and burden has evolved from one based on clinical activity to one based on radiologic criteria (eg, number of new/enlarging T2 lesions, number of gadolinium-enhancing [Gd+] lesions, and brain atrophy/black holes). Treatment has moved from slowing disease progression to treatments (eg, natalizumab, fingolimod, interferon beta-1b [IFN-β-1b]) that improve and sustain function.